Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the
buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal
system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back
pain currently treated with oral opioids. The double-blind treatment intervention duration is
12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will
be provided to all subjects in addition to study drug.